11,394 Shares in Dynavax Technologies Co. (NASDAQ:DVAX) Acquired by SkyView Investment Advisors LLC

SkyView Investment Advisors LLC bought a new stake in Dynavax Technologies Co. (NASDAQ:DVAX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 11,394 shares of the biopharmaceutical company’s stock, valued at approximately $127,000.

Other large investors also recently added to or reduced their stakes in the company. Renaissance Technologies LLC boosted its position in Dynavax Technologies by 2.2% during the second quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company’s stock worth $27,830,000 after purchasing an additional 53,600 shares during the period. Great Point Partners LLC raised its stake in Dynavax Technologies by 87.7% during the 2nd quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company’s stock valued at $26,660,000 after purchasing an additional 1,109,080 shares during the last quarter. Millennium Management LLC acquired a new position in shares of Dynavax Technologies during the second quarter valued at about $17,615,000. Mizuho Markets Americas LLC grew its position in Dynavax Technologies by 17.4% during the third quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company’s stock worth $15,369,000 after buying an additional 204,475 shares in the last quarter. Finally, Bank of Montreal Can lifted its position in shares of Dynavax Technologies by 8.3% in the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after acquiring an additional 82,449 shares during the period. 96.96% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and issued a $29.00 target price on shares of Dynavax Technologies in a report on Friday, November 8th.

Dynavax Technologies Price Performance

NASDAQ DVAX opened at $12.99 on Friday. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The business has a 50 day simple moving average of $11.98 and a 200 day simple moving average of $11.47. The stock has a market cap of $1.71 billion, a price-to-earnings ratio of 99.93 and a beta of 1.33.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.